Basic Ebixa Information

• INN (International Nonproprietary Name): Memantine
• Brand Names Available In United Kingdom: Ebixa, Memantine Accord — tablets 10mg; oral solution 10mg/mL; some generics supply oral drops.
• ATC Code: N06DX01 — “N06” (Psychoanaleptics), “DX01” (Other anti-dementia drugs, memantine)
• Forms & Dosages: Tablets 5mg and 10mg (common 10mg); oral solution 10mg/mL in 30mL or 50mL bottles with dosing syringe/pipette; XR capsules (Namenda XR) 7mg/14mg/21mg/28mg available in North America but not common in the UK.
• Manufacturers In United Kingdom: Main marketing authors include Accord and Lundbeck; other EU generics from Teva, Mylan, Sandoz, Zentiva, Actavis and Genericon are widely available.
• Registration Status In United Kingdom: Authorised prescription-only medicine for moderate to severe Alzheimer’s disease; several generics are marketed.
• OTC / Rx Classification: Prescription only (Rx).

Preamble — Immediate Safety Instructions And Daily-Life Integration For United Kingdom Patients

Memantine (INN: memantine; ATC N06DX01) is a prescription-only medicine in the UK and EU.

Do not buy memantine from unregulated overseas websites.

If an overdose is suspected, call 999 or go straight to A&E without delay.

Report any adverse reaction via the MHRA Yellow Card scheme or speak to your GP or local pharmacist.

Keep tablets in their original packaging and do not transfer loose tablets into unlabelled containers.

The oral solution (10 mg/mL) must be measured using the supplied syringe or pipette.

Store memantine at room temperature, typically 20–25°C, and protect the oral solution from light.

When attending A&E, carry NHS red/blue repeat prescription details or hospital clinic letters if available.

Use a weekly pillbox, phone reminders or a linked NHS app to help with dosing adherence.

Tell the DVLA and your insurer if memantine causes dizziness or episodes of confusion that could affect driving.

Community pharmacists at Boots, LloydsPharmacy or Superdrug can counsel on dosing, supply repeat prescriptions and demonstrate oral-syringe technique.

Emergency Actions — Checklist:

• If unconscious, call 999 immediately.
• If there are severe symptoms after overdose (breathing difficulty, seizures, hallucinations), go to A&E.
• Keep the medication packet to show clinicians and note the time and amount taken.
• Report suspected adverse reactions to the MHRA Yellow Card scheme after stabilisation.

Daily Tips:

• Match a dose to an established routine such as breakfast or tea-time to reduce missed doses.
• Use an NHS prescription reminder or set phone alarms for twice-daily dosing.
• Keep a one-page med list and pharmacy contact in your wallet for emergencies.

Everyday Use & Best Practices

Morning Vs Evening Dosing

Most adults start memantine at 5mg once daily and titrate up weekly by 5mg increments to 10mg twice daily (total 20mg/day).

Many carers split the maintenance doses into morning and early evening to minimise dizziness at night.

UK patients prescribed Namenda XR should note this is an extended-release once-daily product and follows a different titration schedule (7mg to 28mg) used primarily in North America.

Taking With Or Without Meals

Memantine may be taken with or without food without affecting absorption.

Pairing a pill with a regular UK mealtime or a tea-time helps reduce missed doses.

Avoid taking a dose immediately before bedtime if memantine causes insomnia or vivid dreams.

Practical Aids

Use an AM/PM pillbox to separate morning and evening doses and reduce errors.

Set linked phone alarms that coincide with NHS repeat prescription reminders.

Ask a pharmacist at Boots or LloydsPharmacy to demonstrate how to use the dosing syringe for the 10 mg/mL oral solution.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Do not use memantine in anyone with a known allergy to memantine or excipients.

Exercise caution or avoid memantine in severe renal impairment; dose reduction is required for CrCl 5–29 mL/min to a maximum of 5mg twice daily.

Use caution in people with a history of seizures and in conditions that alkalinise urine which can increase memantine levels.

Discuss use in pregnancy or breastfeeding with the prescriber as safety is not established.

• Absolute Contraindication: Known hypersensitivity to memantine or any excipient.
• Relative Concerns: Severe renal impairment, seizure history, conditions causing urine alkalinisation.

Activities To Limit (Driving, Work Safety)

Memantine can cause dizziness, confusion and blurred vision in some patients.

Avoid driving, operating heavy machinery or performing hazardous work until the individual knows how memantine affects them.

Follow DVLA guidance and tell the GP if cognitive fluctuations could impair driving competence.

Practical Safety Card:

• Keep a one-page safety card with prescriber and pharmacy contacts in your wallet.
• Use a simple checklist before returning to driving: no recent dizziness, no sudden confusion, stable on dose for at least one week.

Dosage & Adjustments

General Regimen (NHS Guidance)

Titration commonly starts at 5mg once daily and increases by 5mg each week to reach 10mg twice daily (20mg/day) for moderate–severe Alzheimer’s disease.

Extended-release Namenda XR uses a different schedule (7mg→28mg once daily) and is not the standard UK formulation.

Special Cases (Elderly, Comorbidities)

Older adults generally follow the usual regimen but should have renal function monitored regularly.

Severe renal impairment (CrCl 5–29 mL/min) requires a maximum of 5mg twice daily.

Memantine is not approved for children.

Dispensing Checklist For Pharmacists:

• Confirm indication and titration schedule with the prescriber.
• Check recent renal function (eGFR/CrCl) before dispensing.
• Provide written dosing instructions and demonstrate oral-syringe use for solution.

User Testimonials

Positive Reports From United Kingdom Patients

Some carers report stabilisation in daily routines and reduced agitation when memantine is added to existing treatment.

Improved mealtime participation and calmer evenings are commonly described on NHS forums and Patient.info threads.

Common Challenges (Patient.info, NHS Forums)

Initial side effects during titration often include dizziness, headache and constipation.

Occasional increased confusion during dose changes and the perception of limited benefit over months are frequently reported.

Adherence can be difficult when swallowing tablets, and the 10 mg/mL oral solution or small 5 mg tablets can help.

Practical Monitoring Checklist From Users:

• Keep a weekly symptoms diary noting sleep, agitation and daily tasks.
• Compare activity levels week-to-week and bring the diary to GP reviews.
• Discuss combination therapy with clinicians if appropriate.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

In the UK memantine is commonly supplied as Ebixa or generic Memantine Accord via GP prescription and dispensed at community pharmacies such as Boots, LloydsPharmacy and Superdrug.

A number of pharmacies stock the oral solution 10 mg/mL and supply the correct dosing syringe.

Do not purchase from unregulated overseas websites that do not require a UK prescription.

Price Comparison (NHS Prescription Charge Vs Private)

In England the NHS prescription charge applies per item unless the patient is exempt; Scotland, Wales and Northern Ireland provide free NHS prescriptions.

Generic memantine brands often reduce out-of-pocket cost compared with brand-name Ebixa.

When using an online pharmacy service ensure it is GPhC-registered and that a UK prescriber reviews the order.

Purchasing Note: In our online pharmacy, ebixa is available without a prescription, with discreet delivery to the United Kingdom in 5–14 days.

Safe Online Purchase Checklist:

• Confirm GPhC registration of the online pharmacy.
• Ensure a UK prescriber reviews and signs the prescription.
• Keep receipts and batch details for Yellow Card reporting where necessary.

What’s Inside & How It Works

Ingredients Overview

The active ingredient is memantine hydrochloride (INN memantine).

Available forms include 5mg and 10mg tablets and an oral solution of 10 mg/mL supplied in 30–50 mL bottles with a dosing syringe.

XR capsules (Namenda XR) exist in North America but are not commonly used in the UK.

Mechanism Basics Explained Simply

Memantine is an NMDA receptor antagonist that modifies glutamatergic activity in the brain.

By reducing pathological NMDA receptor overactivation, memantine can help stabilise neuronal signalling linked to confusion and agitation in later-stage Alzheimer’s.

It is symptomatic treatment and not disease-modifying.

Patient-Friendly Summary:

• Think of memantine as a brain stabiliser that may reduce confusion and improve engagement.
• It is often used with a cholinesterase inhibitor for complementary effects.

Main Indications

Approved Uses (MHRA Listing)

Memantine is licensed for moderate to severe Alzheimer’s disease as symptomatic therapy.

The typical maintenance dose is 10mg twice daily after titration.

Off-Label Uses In United Kingdom Clinics

Some specialists trial memantine in vascular or mixed dementia or for behavioural symptoms, but evidence varies and these uses should be documented as off-label.

Documentation Checklist:

• Ensure indication appears on repeat prescriptions and MAR charts.
• Record treatment goals and planned review dates.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

No major food interactions are established for memantine.

Alcohol can worsen dizziness, sedation and cognitive effects and should be limited.

Tea or coffee have no specific interaction but stimulants may affect sleep when doses are taken late.

Drug Conflicts (MHRA Yellow Card Reports)

Drugs that alkalinise urine can reduce memantine elimination and raise plasma levels.

Concurrent use with other NMDA-active agents such as amantadine or ketamine requires review.

MHRA Yellow Card reports sometimes record confusion, hallucinations or falls when memantine is combined with other CNS medicines.

Medication Reconciliation Checklist:

• Check all prescribed and OTC medicines and supplements each time memantine is dispensed.
• Review drugs that affect renal clearance or urine pH.
• Advise carers to inform hospital teams of memantine when admitted.

Latest Evidence & Insights

Key United Kingdom & EU Studies 2022–2025

Recent reviews from 2022–2025 continue to show modest symptomatic benefits of memantine for cognition and function in moderate–severe Alzheimer’s.

Evidence indicates potential reduction in behavioural symptoms for some patients, especially when combined with a cholinesterase inhibitor.

Practical Interpretation For Patients And Carers

Clinicians tend to run an individualised trial and review outcomes at 3–6 months to decide on continued therapy.

Use a simple symptom log to capture sleep, agitation and engagement as measurable outcomes.

Ask the prescriber for evidence summaries relevant to the individual case and document planned review dates and discontinuation criteria.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

AChE inhibitors such as donepezil, rivastigmine and galantamine are first-line for mild–moderate Alzheimer’s.

• Donepezil: once-daily dosing and generally well tolerated.
• Rivastigmine: patch option useful for swallowing difficulties.
• Galantamine: offers cholinesterase inhibition with nicotinic receptor modulation.

Combining Memantine With AChE Inhibitors (Practice Points)

Combination therapy can offer incremental benefits for some patients but increases the need for monitoring for side effects.

Decision Checklist For Combination Use:

• Agree goals with prescriber and record them clearly.
• Perform baseline monitoring and review at 3–6 months.
• Consider stopping if no clinically meaningful benefit is observed.

Regulation Snapshot

MHRA Approval & Key Points

Memantine (INN memantine; ATC N06DX01) is authorised in the UK as a prescription-only medicine for moderate–severe Alzheimer’s disease.

Several generics such as Ebixa and Memantine Accord are marketed in Europe.

NHS Prescribing Framework (Repeat Prescriptions, Hospital Vs GP)

Initiation may occur in memory clinics or secondary care, with many GPs continuing prescriptions under shared-care agreements.

Pharmacies such as Boots and LloydsPharmacy routinely dispense memantine and can provide counselling at point of supply.

Practical Prescribing Checklist:

• Confirm whether initiation was hospital-led and whether a shared-care protocol exists.
• Document follow-up appointments and monitoring responsibilities.

FAQ Section

Will Memantine Cure Alzheimer’s?

No — memantine is symptomatic treatment and does not cure or modify the underlying disease process.

How Soon Will I See Effects / What If Side Effects Occur?

Some carers notice changes within weeks, but clinicians usually allow around three months to judge benefit.

If side effects such as dizziness, headache, constipation or confusion occur, contact the GP or pharmacist for advice on dose adjustment or slower titration.

Can I Stop Memantine And How Is This Managed?

Do not stop memantine abruptly without clinical advice except in the case of a severe adverse event.

Planned discontinuation should be documented in GP and hospital notes and agreed with the prescriber.

Decision Checklist For Side Effects:

• Assess severity and onset of symptoms.
• Consider dose reduction or slower titration under clinician supervision.
• If severe, arrange medical review and consider stopping immediately if directed by prescriber.

Guidelines For Proper Use

United Kingdom Pharmacist Counselling Style

Pharmacists should use plain language, confirm the indication, and demonstrate oral-syringe use for the 10 mg/mL solution.

They should review concomitant medicines, check recent renal function and warn about common side effects such as dizziness, constipation and headache.

Offer adherence aids such as weekly boxes and signpost to memory clinics or the Alzheimer’s Society for extra support.

NHS Patient Support Advice

Patients should receive a clear treatment plan with start/titrate schedule, a planned review date (commonly 3–6 months) and monitoring parameters.

Use NHS dementia support services and local Alzheimer’s Society branches for carer support and practical advice.

Provide a one-page written summary at dispensing and a checklist for carers that includes safety, monitoring and contact numbers.

Delivery Across United Kingdom

Final Notes

Keep all memantine dosing information and clinic letters together to show at reviews.

Report any new or unexpected adverse events to the MHRA Yellow Card scheme and discuss concerns with the GP or community pharmacist.

Use a symptoms diary to support clinical reviews and to decide whether memantine provides a meaningful benefit for daily life.

The pharmacy can provide generic options such as Memantine Accord to help reduce cost and supply the oral solution with the correct dosing syringe.